Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
119M
-
Number of holders
-
249
-
Total 13F shares, excl. options
-
91.9M
-
Shares change
-
+10.4M
-
Total reported value, excl. options
-
$3.61B
-
Value change
-
+$407M
-
Put/Call ratio
-
0.37
-
Number of buys
-
143
-
Number of sells
-
-85
-
Price
-
$39.29
Significant Holders of CYTOKINETICS INC - COMMON STOCK (CYTK) as of Q2 2022
286 filings reported holding CYTK - CYTOKINETICS INC - COMMON STOCK as of Q2 2022.
CYTOKINETICS INC - COMMON STOCK (CYTK) has 249 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91.9M shares
of 119M outstanding shares and own 76.99% of the company stock.
Largest 10 shareholders include BlackRock Inc. (13.4M shares), VANGUARD GROUP INC (8.96M shares), CITADEL ADVISORS LLC (4.64M shares), STATE STREET CORP (4.5M shares), WELLINGTON MANAGEMENT GROUP LLP (3.87M shares), Polar Capital Holdings Plc (3.03M shares), LORD, ABBETT & CO. LLC (2.99M shares), RTW INVESTMENTS, LP (2.56M shares), PFM Health Sciences, LP (2.47M shares), and FARALLON CAPITAL MANAGEMENT LLC (2.25M shares).
This table shows the top 249 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.